Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy

Allen, 2017, A systematic review of the psychobiological burden of informal caregiving for patients with dementia: focus on cognitive and biological markers of chronic stress, Neurosci. Biobehav. Rev., 73, 123, 10.1016/j.neubiorev.2016.12.006 Allen, 2015, Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT, J. Affect. Disord., 186, 306, 10.1016/j.jad.2015.06.033 Andrews, 2015, Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response, Neurosci. Biobehav. Rev., 51, 164, 10.1016/j.neubiorev.2015.01.018 Badawy, 2017, Tryptophan availability for kynurenine pathway metabolism across the life span: control mechanisms and focus on aging, exercise, diet and nutritional supplements, Neuropharmacology, 112, 248, 10.1016/j.neuropharm.2015.11.015 Booij, 2005, Acute tryptophan depletion as a model of depressive relapse, Br. J. Psychiatry, 187, 148, 10.1192/bjp.187.2.148 Cervenka, 2017, Kynurenines: tryptophan's metabolites in exercise, inflammation, and mental health, Science, 357, 10.1126/science.aaf9794 Clarke, 2009, Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort, BMC Gastroenterol., 9, 6, 10.1186/1471-230X-9-6 Clarke, 2017, The kynurenine pathway in health and disease, Neuropharmacology, 112, 235, 10.1016/j.neuropharm.2016.08.029 Dowlati, 2010, A meta-analysis of cytokines in major depression, Biol. Psychiatr., 67, 446, 10.1016/j.biopsych.2009.09.033 Drysdale, 2017, Resting-state connectivity biomarkers define neurophysiological subtypes of depression, Nat. Med., 23, 29 Guloksuz, 2015, The impact of electroconvulsive therapy on the tryptophan–kynurenine metabolic pathway, Brain Behav. Immun., 48, 48, 10.1016/j.bbi.2015.02.029 Guloksuz, 2014, The immune system and electroconvulsive therapy for depression, J. ECT, 30, 132, 10.1097/YCT.0000000000000127 Gururajan, 2016, Molecular biomarkers of depression, Neurosci. Biobehav. Rev., 64, 101, 10.1016/j.neubiorev.2016.02.011 Gururajan, 2016, MicroRNAs as biomarkers for major depression: a role for let-7b and let-7c, Transl. Psychiatry, 6, e862, 10.1038/tp.2016.131 Haile, 2014, Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression, Int. J. Neuropsychopharmacol., 17, 331, 10.1017/S1461145713001119 Hofmann, 2010, The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review, J. Consult. Clin. Psychol., 78, 169, 10.1037/a0018555 Insel, 2014, The NIMH research domain criteria (RDoC) project: precision medicine for psychiatry, Am. J. Psychiatr., 171, 395, 10.1176/appi.ajp.2014.14020138 Kalsi, 2011, The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use, Emerg. Health Threats J., 4, 7107, 10.3402/ehtj.v4i0.7107 Kelly, 2017, Dimensional thinking in psychiatry in the era of the research domain criteria (RDoC), Ir. J. Psychol. Med. Kennedy, 2015, Acute tryptophan depletion reduces kynurenine levels: implications for treatment of impaired visuospatial memory performance in irritable bowel syndrome, Psychopharmacology, 232, 1357, 10.1007/s00213-014-3767-z Kennedy, 2017, Kynurenine pathway metabolism and the microbiota-gut-brain axis, Neuropharmacology, 112, 399, 10.1016/j.neuropharm.2016.07.002 Khalili-Mahani, 2015, Effect of subanaesthetic ketamine on plasma and saliva cortisol secretion, Br. J. Anaesth., 115, 68, 10.1093/bja/aev135 Kim, 2016, The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression, Prog. Neuropsychopharmacol. Biol. Psychiatr., 64, 277, 10.1016/j.pnpbp.2015.06.008 Köhler, 2017, Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies, Acta Psychiatr. Scand., 135, 373, 10.1111/acps.12698 Luckenbaugh, 2014, Do the dissociative side effects of ketamine mediate its antidepressant effects?, J. Affect. Disord., 159, 56, 10.1016/j.jad.2014.02.017 Maes, 1997, Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression, Cytokine, 9, 853, 10.1006/cyto.1997.0238 Miller, 2013, Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression, Neuropsychopharmacology, 38, 1607, 10.1038/npp.2013.140 Murrough, 2013, Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression, Biol. Psychiatr., 74, 250, 10.1016/j.biopsych.2012.06.022 Myint, 2007, Kynurenine pathway in major depression: evidence of impaired neuroprotection, J. Affect. Disord., 98, 143, 10.1016/j.jad.2006.07.013 Naughton, 2014, A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action, J. Affect. Disord., 156, 24, 10.1016/j.jad.2013.11.014 O'Brien, 2004, Cytokines: abnormalities in major depression and implications for pharmacological treatment, Hum. Psychopharmacol., 19, 397, 10.1002/hup.609 O'Connor, 2012, Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression, Mol. Psychiatr., 17, 359, 10.1038/mp.2011.162 O'Connor, 2009, Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice, Mol. Psychiatr., 14, 511, 10.1038/sj.mp.4002148 O'Farrell, 2017, Stress-related regulation of the kynurenine pathway: relevance to neuropsychiatric and degenerative disorders, Neuropharmacology, 112, 307, 10.1016/j.neuropharm.2015.12.004 O'Leary, 2015, Faster, better, stronger: towards new antidepressant therapeutic strategies, Eur. J. Pharmacol., 753, 32, 10.1016/j.ejphar.2014.07.046 Pariante, 2008, The HPA axis in major depression: classical theories and new developments, Trends Neurosci., 31, 464, 10.1016/j.tins.2008.06.006 Park, 2017, Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression, J. Psychiatr. Res., 84, 113, 10.1016/j.jpsychires.2016.09.025 Pradhan, 2015, Ketamine, transcranial magnetic stimulation, and depression specific yoga and mindfulness based cognitive therapy in management of treatment resistant depression: review and some data on efficacy, Depress. Res. Treat, 2015, 842817 Prudic, 1996, Resistance to antidepressant medications and short-term clinical response to ECT, Am. J. Psychiatr., 153, 985, 10.1176/ajp.153.8.985 Prudic, 1990, Medication resistance and clinical response to electroconvulsive therapy, Psychiatr. Res., 31, 287, 10.1016/0165-1781(90)90098-P Pruessner, 2003, Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change, Psychoneuroendocrinology, 28, 916, 10.1016/S0306-4530(02)00108-7 Raison, 2006, Cytokines sing the blues: inflammation and the pathogenesis of depression, Trends Immunol., 27, 24, 10.1016/j.it.2005.11.006 Ramachandraih, 2011, Antidepressants: from MAOIs to SSRIs and more, Indian J. Psychiatr., 53, 180, 10.4103/0019-5545.82567 Ruddick, 2006, Tryptophan metabolism in the central nervous system: medical implications, Expet Rev. Mol. Med., 8, 1, 10.1017/S1462399406000068 Sackeim, 2001, Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial, JAMA, 285, 1299, 10.1001/jama.285.10.1299 Sackeim, 1990, The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression, J. Clin. Psychopharmacol., 10, 96, 10.1097/00004714-199004000-00004 Sanacora, 2017, A consensus statement on the use of ketamine in the treatment of mood disorders, JAMA Psychiatr., 74, 399, 10.1001/jamapsychiatry.2017.0080 Sarubin, 2017, The sex-dependent role of the glucocorticoid receptor in depression: variations in the NR3C1 gene are associated with major depressive disorder in women but not in men, Eur. Arch. Psychiatr. Clin. Neurosci., 267, 123, 10.1007/s00406-016-0722-5 Schwarcz, 2017, The kynurenine pathway and the brain: challenges, controversies and promises, Neuropharmacology, 112, 237, 10.1016/j.neuropharm.2016.08.003 Schwieler, 2016, Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients, J. Neuroinflammation, 13, 51, 10.1186/s12974-016-0517-7 Semkovska, 2016, Bitemporal versus high-dose unilateral twice-weekly electroconvulsive therapy for depression (EFFECT-Dep): a pragmatic, randomised, non-inferiority trial, Am. J. Psychiatr., 173, 408, 10.1176/appi.ajp.2015.15030372 Short, 2017, Side-effects associated with ketamine use in depression: a systematic review, Lancet Psychiatr. Singh, 2016, A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression, Am. J. Psychiatr., 173, 816, 10.1176/appi.ajp.2016.16010037 Sorgdrager, 2017, The association between the hypothalamic pituitary adrenal axis and tryptophan metabolism in persons with recurrent major depressive disorder and healthy controls, J. Affect. Disord., 222, 32, 10.1016/j.jad.2017.06.052 Stalder, 2016, Assessment of the cortisol awakening response: expert consensus guidelines, Psychoneuroendocrinology, 63, 414, 10.1016/j.psyneuen.2015.10.010 Sublette, 2011, Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder, Brain Behav. Immun., 25, 1272, 10.1016/j.bbi.2011.05.002 Trivedi, 2006, Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice, Am. J. Psychiatr., 163, 28, 10.1176/appi.ajp.163.1.28 U.K. ECT Review Group, 2003, Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis, Lancet, 361, 799, 10.1016/S0140-6736(03)12705-5 World Health Organisation, 2016 Yang, 2015, Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression, Biol. Psychiatr., 77, e19, 10.1016/j.biopsych.2014.06.021 Zanos, 2016, NMDAR inhibition-independent antidepressant actions of ketamine metabolites, Nature, 533, 481, 10.1038/nature17998 Zarate, 2006, A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression, Arch. Gen. Psychiatr., 63, 856, 10.1001/archpsyc.63.8.856